30 related articles for article (PubMed ID: 38446900)
1. Immunocytokines: amplification of anti-cancer immunity.
Davis CB; Gillies SD
Cancer Immunol Immunother; 2003 May; 52(5):297-308. PubMed ID: 12700945
[TBL] [Abstract][Full Text] [Related]
2. Cytokine/Antibody Fusion Protein Design and Evaluation.
Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral nanobody-IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice.
Lutz EA; Jailkhani N; Momin N; Huang Y; Sheen A; Kang BH; Wittrup KD; Hynes RO
PNAS Nexus; 2022 Nov; 1(5):pgac244. PubMed ID: 36712341
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
5. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.
Boissel L; Betancur-Boissel M; Lu W; Krause DS; Van Etten RA; Wels WS; Klingemann H
Oncoimmunology; 2013 Oct; 2(10):e26527. PubMed ID: 24404423
[TBL] [Abstract][Full Text] [Related]
6. Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect
Silvestre RN; Eitler J; de Azevedo JTC; Tirapelle MC; Fantacini DMC; de Souza LEB; Swiech K; Covas DT; Calado RT; Montero PO; Malmegrim KCR; Figueiredo ML; Tonn T; Picanço-Castro V
Front Immunol; 2023; 14():1226518. PubMed ID: 37818365
[TBL] [Abstract][Full Text] [Related]
7. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
[TBL] [Abstract][Full Text] [Related]
8. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
9. Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.
Zekri L; Hagelstein I; Märklin M; Klimovich B; Christie M; Lindner C; Kämereit S; Prakash N; Müller S; Stotz S; Maurer A; Greve C; Schmied B; Atar D; Rammensee HG; Jung G; Salih HR
Sci Transl Med; 2024 Mar; 16(737):eadh1988. PubMed ID: 38446900
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
11. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]